Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
Find a Broker »
- li>
- li>
- li>
- li>
- li>
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.40 | 0.26 | 50.18 |
| EPS, GAAP | 0.41 | 0.25 | 0.25 |
| Consensus Estimate | 0.53 | 0.35 | 52.39 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 1.40 | 0.99 | 41.73 |
| EPS, GAAP | 1.28 | 0.91 | 40.45 |
| Consensus Estimate | 2.05 | 1.30 | 57.69 |
| ALXN | Industry Average | |
| P/E (TTM) | 74.30 | NA |
| P/E (Forward) | 34.48 | NA |
| PEG Ratio | 0.97 | 2.20 |
| Price/Sales | 16.85 | 18.91 |
| Beta | 0.77 | 0.70 |
| 4/2/2013 | UBS Top Picks for Second Quarter for 25 Percent Gains (ALXN, ACI, C, CIE, DAL, HAL, BLOX, KRA, MNST, NCT, ROST, TIBX, WCRX, WFM) (24/7 Wall St) |
| 2/28/2013 | ETF Folly: Biotech ETFs, Nothing but Confusion (24/7 Wall St) |
| 2/20/2013 | Broad Strokes for Family Fund (WSJ.com) |
| 2/20/2013 | Top Analyst Upgrades and Downgrades (ACMP, ALXN, ADI, BIDU, BCS, ESRX, GMCR, LOW, MM, NTSP, RDN, SEE, SPLS, HOT, WIN) (24/7 Wall St) |
| 1/18/2013 | Analyst Calls Cancer Treatments Major Biotech Focus in 2013 (AMGN, GSK, ALXN, ARIA, CELG, INCY, ONXX) (24/7 Wall St) |
| 1/9/2013 | The Big Biotech Winners and Losers for 2013 (AMGN, BIIB, CELG, GILD, ALXN, ARIA, CBST, INCY, JAZZ, MDVN, ONXX, THRX, VPHM, VVUS) (24/7 Wall St) |